PET/CT is approved by Medicare for us in staging, restaging and detecting recurrence in colorectal cancer.
2004 Colorectal Statistics:
Estimated New Cases
- Colon 106,370
- Rectal 40,570
Estimated New Deaths
- Colon 56,730
*All cancer statistics obtained from the American Cancer Society’s Cancer Facts and Figures available at www.cancer.org.
Colorectal Cancer and FDG PET Imaging Statistics**
Table 1: Utility of PET Imaging in Colorectal Cancer Diagnosis/Staging (N=134)
For this patient population there was a 37% change in the way the physician managed the patients based upon the PET scan.
Table 3: Utility of PET Imaging in Colorectal Cancer Recurrence (N=2244)
For this patient population there was a 24% change in the way the physician managed the patient’s disease based upon the results of the PET scan.
Table 3: Utility of PET Imaging in Breast Cancer Diagnosis/Staging (N=65)
For this patient population there was a 32% change in the way the physician managed the patient based upon the PET scan.
** Reprinted by permission of the Society of Nuclear Medicine from: Gambhir, Sanjiv S., Czernin, Johannes, Schwimmer, Judy, Silverman, Daniel H.S., Coleman, R. Edward, Phelps, Michael E. “A Tabulated Summary of the FDG PET Literature” J Nucl Med 2001 42: 1-93.
Patient: 68yo male initially diagnosed with colon cancer three years prior. The patient underwent surgery and chemotherapy. Patient now with rising CEA and CT with a solitary liver lesion in the right lobe Patient being considered for surgery. PET/CT was ordered to restage the patient.
Results: PET/CT revealed multiple tumors within the bones, liver and abdominal lymph nodes that were not seen with CT. PET/CT helped the patient avoid a futile surgery, and directed the patient to a more appropriate therapy